At Firebrick, we understand how to market pharmaceuticals and have extensive experience in the infectious diseases and respiratory drug markets at an international level.

The Firebrick compound is already approved for use as an OTC for other indications but has never been developed as a nasal spray or proposed as a treatment for the common cold. This means that the regulatory pathway to market is already paved for Firebrick and we can expect a fast track to market. In fact, the new nasal spray could be on the market in as little as three years.